MAO/DETECTION OF ANTIBODIES & PROTEINS--ISOLATION OF VIR

艾滋病毒临床前疫苗开发主协议计划是 启动以使NIAID能够提供资源以加速 开发有前景的疫苗方法。在这个节目中，一系列 已经启动了疫苗研究，以评估候选疫苗和 非人灵长类动物的艾滋病疫苗原型。这些研究是专门设计的 获取更多有关疗效和最佳呈现方式的信息 正在进行人类第一阶段临床试验的候选艾滋病毒疫苗或 建议用于此类试验以及该试验的SIV疫苗原型 作为这些艾滋病毒疫苗的类型，其他疫苗研究将评估原型 提供新颖呈现系统的HIV或SIV疫苗可能能够 引发广泛的交叉反应免疫反应，或者已经显示出 有希望的初步结果。NIAID已经启动了协作 与同意提供艾滋病毒和SIV的研究人员的安排 非人灵长类动物免疫疫苗。在所有疫苗中 研究表明，非人灵长类动物在免疫后将受到挑战 确定是否可以获得免受感染或疾病的保护。 主协议计划E类承包商，包括 上述承包商将为以下项目提供实验室支持 这些不同的疫苗研究。实验室的支持工作是分开的 分成两部分。A部分涉及接种艾滋病毒疫苗的动物 和SIV挑战，B部分检测与免疫的动物有关 用SIV疫苗和用SIV挑战。在所有情况下，化验将是 用酶联免疫吸附试验和免疫印迹法检测体液免疫 免疫猕猴的反应。病毒分离，如共培养和 将进行有限稀释以确定病毒感染是否 发生在病毒攻击之后。E类承建商将维持 每项研究的测试结果数据库，并将传输数据 以电子方式发送到艾滋病疫苗评估小组的统计和 协调中心。此外，E类承建商将提供 进行生物安全二级或三级实验室的设施和设备 工作。

The HIV Preclinical Vaccine Development Master Agreement Program was initiated to enable the NIAID to provide resources to accelerate the development of promising vaccine approaches. Under this program, a series of vaccine studies have been initiated to evaluate candidate and prototype AIDS vaccines in nonhuman primates. These studies are designed to obtain more information about the efficacy and optimum presentation of candidate HIV vaccines that are in human Phase I clinical trials or proposed for such trials as well as prototype SIV vaccines of the same type as these HIV vaccines Other vaccine studies will evaluate prototype HIV or SIV vaccines that offer novel presentation systems, may be capable of eliciting broadly cross-reactive immune responses, or have shown promising preliminary results. NIAID has initiated collaborative arrangements with researchers who have agreed to provide HIV and SIV vaccines for immunization of nonhuman primates. In all of the vaccine studies, the nonhuman primates will be challenged after immunization to determine if protection from infection or from disease can be obtained. The contractors in Category E of the Master Agreement Program, including the contractor listed above, will provide the laboratory support for these various vaccine studies. The laboratory support work is divided into two parts. Part A pertains to animals immunized with HIV vaccines and challenged with SHIV, and Part B assays pertain to animals immunized with SIV vaccines and challenged with SIV. In all cases assays will be performed such as ELISA and Western Blots to assess the humoral immune responses of immunized macaques. Virus isolations such as co-culture and limiting dilution will be performed to determine if virus infection has occurred after virus challenge. The Category E contractors will maintain a test results database for each study, and will transfer data electronically to the AIDS Vaccine Evaluation Group Statistical and Coordinating Center. In addition, the Category E contractors will provide facilities and equipment to conduct biosafety level 2 or 3 laboratory work.